Nessan Bermingham, Triplet Therapeutics CEO
October 12, 2022 10:01 AM EDT
R&D

At­las-backed biotech fo­cused on Hunt­ing­ton's dis­ease shuts down less than three years af­ter launch

Max Gelman

Senior Editor

An At­las-found­ed biotech qui­et­ly shut down this week, with the CEO post­ing on­ly a short state­ment on LinkedIn to an­nounce the move.

Triplet Ther­a­peu­tics is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M

In­tel­lia touts first clin­i­cal out­comes on CRISPR-based AT­TR amy­loi­do­sis as­set

Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times